Panelists discuss how early detection barriers include nonspecific symptoms like progressive dyspnea that are often misattributed to more common conditions, leading to delayed diagnosis and the need for improved diagnostic algorithms using biomarkers and imaging.
Clinical Presentation and Symptom Recognition
Early symptoms of pulmonary arterial hypertension are typically subtle and nonspecific, leading to frequent diagnostic delays and misdiagnoses. Progressive dyspnea on exertion represents the most common initial symptom, accompanied by fatigue and rapid exhaustion during physical activity. More severe symptoms like syncope and peripheral edema typically occur later in disease progression, often indicating advanced right heart dysfunction and poor prognosis.
The nonspecific nature of early PAH symptoms contributes to diagnostic challenges, with patients often experiencing months or years of evaluation by multiple physicians before receiving an accurate diagnosis. Recent European guidelines have introduced screening algorithms for general practitioners, incorporating ECG and biomarker measurements (BNP or NT-proBNP) to identify patients who warrant echocardiographic evaluation. While these tools lack perfect sensitivity, they provide valuable screening capabilities for symptomatic patients.
Improved diagnostic approaches emphasize the importance of reassessing patients who fail to respond to initial treatments for more common conditions like asthma or COPD. When patients continue experiencing unexplained dyspnea despite standard therapy, further evaluation becomes essential. This systematic approach, combined with increased awareness among healthcare providers, aims to reduce diagnostic delays and facilitate earlier referral to specialized pulmonary hypertension centers.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More